Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma

Abstract

BackgroundToceranib phosphate (Palladia) has a reported objective response rate of 25% in both canine apocrine gland anal sac adenocarcinoma (AGASACA) and thyroid carcinoma (TC), with stable disease occurring in an additional 50-60% of dogs. The basis for the observed responses to toceranib is not known. The purpose of this study was to evaluate AGASACA and TC samples for the expression and activation of VEGFR2, PDGFRα, PDGFRβ, KIT and RET to assess whether dysregulation of these receptor tyrosine kinases (RTKs) may contribute to the biologic activity of toceranib.ResultsmRNA for VEGFR2, PDGFRα/β, KIT and RET was detected in all AGASACA samples. mRNA for VEGFR2, PDGFRα/β, and KIT was detected in all TC samples, while mRNA for RET was amplified in 10/15 samples. No phosphorylation of VEGFR2, PDGFRα/β, or KIT was observed on the arrays. However, phosphorylation of RET was detected in 54% of the primary AGASACA and 20% of TC. VEGFR2 was expressed in 19/24 primary and 6/10 metastatic AGASACA and 6/15 TC samples. KIT was present in 8/24 primary and 3/10 metastatic AGASACA and 9/15 TC samples. PDGFRα expression was noted in all tumor samples. In contrast PDGFRβ expression was found in only a few tumor samples but was evident in the stroma of all tumor specimens.ConclusionsKnown targets of toceranib are expressed in both AGASAC and TC. Given the observed expression of VEGFR and PDGFRα/β and phosphorylation of RET, these RTKs merit investigation as to their roles in the biology of AGSACA and TC and their contribution to toceranib’s activity.

A novel approach to treatment of lymphangiosarcoma in a boxer dog

“…), which suggested its action against receptors others than KIT (London et al . , Urie ). Recently, its biological and in vitro activity has been reported in several solid tumours including apocrine gland adenocarcinoma, thyroid carcinoma, nasal carcinoma, metastatic osteosarcoma, and carcinoma of the head and neck (Chon et al .…”

Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour‐bearing dogs: A phase I dose finding study

“…Subsequent off‐label investigation of toceranib further supported a role for the drug in the management of numerous canine neoplasms, including apocrine gland anal sac adenocarcinoma, metastatic osteosarcoma, thyroid carcinoma, head and neck carcinomas, and nasal carcinoma . Supporting these clinical observations is in vitro evidence that several of these tumour types express at least 1 of the molecular targets of toceranib …”

Expression of VEGFR and PDGFR‐α/‐βin 187 canine nasal carcinomas

“…The identified tumour tissue was punched out using a disposable punch biopsy (Punch biopsy, 2 mm, Kai Medical, Solingen, Germany). A total of 20 punches (one of each tissue sample) were re‐embedded in one paraffin tissue block (Leica EG 1160 paraffin embedding station) along with two internal positive controls [canine ASAC (PDGFR), canine granulomatous tissue, (VEGFR)] for which positive expression of VEGFR, PDGFR‐α and PDGFR‐β has already been described …”